YOLFTbeta
Chemomab Therapeutics Ltd DRC

Chemomab Therapeutics Ltd DRC

CMMB · NASDAQ · Healthcare / Biotechnology

1.53USD+0.13 (+9.29%)

Price History

Full chart

Market Stats

Previous Close1.40
Open1.46
Day Range1.39 – 1.58
52-Week Range1.35 – 3.58
Volume85.49K
Market Cap16.12M
P/E (TTM)0.00
Forward P/E12.94
EPS-0.96
Dividend Yield0.00%
Beta0.76
50-Day Avg2.10
200-Day Avg1.84

About

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Adi Mor George Ph.D.
  • Employees0
  • HeadquartersBuilding C, Tel Aviv-Yafo, Israel, 6158101, USA
  • Websitehttps://www.chemomab.com

Leadership

  • Dr. Adi Mor George Ph.D.Co-Founder, Chief Scientific Officer, CEO & Executive Director · b. 1982
  • Ms. Sigal Fattal CPA, M.B.A.Chief Financial Officer · b. 1971
  • Mr. John LawlerChief Development Officer
  • Ms. Barbara L. LindheimConsulting Vice President of Investor & Public Relations, Strategic Communications · b. 1950
  • Dr. David M. Weiner M.B.A., M.D.Interim Chief Medical Officer · b. 1965

Financials

Income Statement

Currency: USD2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue---------000000000
Cost of Revenue47.42K44.12K8.86K3.50M27.58K23.62K19.80K26.25K40.64K51.00K66.00K281.00K80.56K34.02K57.77K66.83K53.25K70.56K
Gross Profit-47.42K-44.12K-8.86K-3.50M--23.62K-19.80K-26.25K-40.64K-51.00K-66.00K-281.00K-80.56K-34.02K-57.77K-66.83K-53.25K-70.56K
Operating Expense4.60M3.43M1.00M1.94M-5.26M6.08M7.11M4.59M9.34M-12.72M-27.41M10.96M12.34M28.48M25.39M14.69M9.50M
Operating Income-4.65M-3.48M-1.01M-5.44M24.18M-5.29M-6.10M-7.13M-4.63M-9.39M12.66M27.12M-11.04M-12.38M-28.53M-25.46M-14.74M-9.57M
EBITDA-2.92M-6.78M-429.00K-4.58M24.18M-5.81M-5.98M-7.46M-4.57M-9.50M12.66M27.12M-10.96M-12.34M-28.48M-25.39M-14.69M-9.50M
Net Income-2.97M-6.82M-584.00K-5.99M24.18M-5.83M-6.00M-7.50M-4.73M-9.81M13.28M27.12M-11.69M-12.49M-27.65M-24.22M-13.95M-8.99M
R&D2.72M2.02M487.66K-15.72M3.99M4.90M5.96M2.34M6.23M7.56M13.30M3.81M6.30M16.98M18.38M11.33M5.83M
Interest Expense--145.74K1.38M---14.16K-5.00K04.23M6.04K111.08K353.00K---

Balance Sheet

Currency: USD2008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets----9.48M--3.52M5.65M2.09M12.76M19.76M12.48M64.35M43.06M22.15M16.96M13.81M
Total Liabilities----6.19M--1.37M2.36M2.70M2.96M4.85M1.67M2.89M6.84M5.15M3.43M1.48M
Total Equity----3.29M--2.14M3.29M-609.00K9.80M12.37M10.80M61.47M36.22M17.00M13.54M12.33M
Cash----5.72M--2.21M4.56M1.45M7.52M17.58M11.67M15.19M13.52M9.29M6.07M7.56M
Total Debt-----------586.00K607.00K343.00K214.00K392.00K324.00K-
Net Debt-----5.72M---2.21M-4.56M-1.45M-7.52M-16.99M-11.07M-14.84M-13.30M-8.90M-5.75M-7.56M

Cash Flow

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-7.38M-3.74M-8.58M-14.18M-16.51M-12.80M-12.38M-20.29M-23.55M-15.46M-11.22M
Investing Cash Flow1.12M77.89K-34.26K-212.31K-95.31K102.72K-45.22M19.46M15.84M2.31M5.43M
Financing Cash Flow4.47M6.06M5.28M20.55M26.71M299.08K61.12M-804.84K3.49M9.91M7.21M
Capital Expenditure87.24K76.06K34.27K212.30K95.31K34.23K239.17K67.73K2.99K4.963.03K
Free Cash Flow-7.47M-3.81M-8.62M-14.39M-16.61M-12.84M-12.62M-20.36M-23.55M-15.46M-11.22M
FCF to OCF101.18%102.04%100.40%101.50%100.58%100.27%101.93%100.33%100.01%100.00%100.03%

Earnings

Report DateMar 12, 2019May 22, 2019Aug 5, 2019Nov 15, 2019Mar 17, 2020May 7, 2020Aug 14, 2020Nov 16, 2020Mar 9, 2021May 13, 2021Aug 13, 2021Nov 12, 2021Mar 9, 2022May 12, 2022Aug 12, 2022Nov 10, 2022Feb 21, 2023May 11, 2023Aug 14, 2023Nov 9, 2023Mar 7, 2024May 9, 2024Aug 21, 2024Nov 14, 2024Mar 5, 2025May 15, 2025Aug 14, 2025Nov 20, 2025Dec 31, 2025May 14, 2026Sep 24, 2026Oct 1, 2026
EPS Estimate-0.15-2.56-2.64-2.93-2.00-1.84-0.11-0.09-1.60-1.72-0.46-0.06-0.10-0.68-0.72-0.92-0.12-0.14-0.16-0.08-0.02-0.06-0.04-0.04-0.01-0.20-0.04-0.04-0.010.000.00-
EPS Actual-0.12-56.00-4.00-34.4031.20-8.00-0.09-0.09-0.06-0.04-0.05-0.05-0.44-0.09-0.11-0.14-0.14-0.16-0.14-0.07-0.27-0.060.05-0.04-0.01-0.14-0.02-0.00-0.00-0.00-1.40-
Surprise20.00%-2087.50%-51.52%-1074.06%1660.00%-334.78%18.18%0.00%96.25%97.67%89.13%16.67%-340.00%86.76%84.72%84.78%-16.67%-14.29%12.50%12.50%-1227.00%0.00%225.00%0.00%20.00%30.00%50.00%90.00%70.00%---
TimingAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-market--

Key Statistics & Ratios

Market Cap16.12M
Enterprise Value6.34M
Trailing P/E0.00
Forward P/E12.94
Price / Sales0.00
Price / Book1.92
EPS-0.96
Book Value1.20
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-7.85M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-82.17%
Return on Assets-46.27%
Shares Outstanding7.33M
Shares Float6.06M
Beta0.76
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 2 analystsTarget 5.00
  • Strong Buy
    1
  • Buy
    1

Ownership Breakdown

Institutions
19.07%
Insiders
12.19%
Retail / Other
68.74%

Top Institutional Holders

  • Advisory Services Network, LLC
    00.00%

Top Fund Holders

  • HBM Healthcare Investments AG Ord
    227.50K2.13%

Stock Splits

  • Aug 26, 20251:4
  • Mar 17, 20211:16